

ORAL ONCOLOGY REFERRAL FORM

TODAY'S DATE _____

CURRENT PATIENT NEW PATIENT

PLEASE FAX REFERRAL FORM TO:

- BiologicTx - NJ**
TEL: 877-567-8087 FAX: 877-567-8089
- BiologicTx - CA**
TEL: 800-404-1963 FAX: 800-404-4595
- BiologicTx - IL**
TEL: 888-892-7607 FAX: 877-567-8089
- Decillion Healthcare**
TEL: 800-622-9321 FAX: 866-548-8849

- Elwyn Specialty Care**
TEL: 855-359-9679 FAX: 610-545-6030
- Factor Support Network**
TEL: 877-376-4968 FAX: 805-482-6324
- Matrix Health**
TEL: 877-337-3002 FAX: 888-385-2805
- Med Center Specialty Pharmacy**
TEL: 855-633-5633 FAX: 304-344-0655
- MedEx BioCare**
TEL: 800-962-6339 FAX: 901-382-3091

Patient Name _____ SS# _____ DOB _____ Male Female
 Street Address _____ Apt# _____ City _____ State _____ Zip _____
 Daytime Tel _____ Cell _____ Email _____ Height _____ Weight _____ BSA _____
 Ship to Patient at Home Work OR Patient will pick up at Physician Office Local Pharmacy Phone _____
 Allergies _____ Comorbidities _____
 Current Medications (if necessary, please fax a complete list) _____

PRACTICE NAME	ADDRESS	PHONE	PRIMARY CONTACT

PRESCRIBER INFORMATION (PLEASE INCLUDE PHYSICIAN NAME AND NPI#)

<input type="checkbox"/>	_____ # _____	<input type="checkbox"/>	_____ # _____	<input type="checkbox"/>	_____ # _____
<input type="checkbox"/>	_____ # _____	<input type="checkbox"/>	_____ # _____	<input type="checkbox"/>	_____ # _____
<input type="checkbox"/>	_____ # _____	<input type="checkbox"/>	_____ # _____	<input type="checkbox"/>	_____ # _____

Insured's Name _____ Relation to Patient _____
 Eligible for Medicare Yes No If yes, Medicare# _____ Prescription Card Yes No If Yes, Carrier _____
 Tel _____ Fax _____ Policy/Group# _____
 Bin# _____ Pcn# _____ RXID# _____ RX Group# _____

Diagnosis ICD-10: _____ Cancer Stage: Stage 0 Stage I Stage II Stage III Stage IV Other _____
 Has patient been treated previously for this condition? Yes No (If patient has been on Xeloda, please indicate dose and duration of therapy below)
 Medications: _____
 Is patient currently on therapy? Yes No Medications: _____
 Will patient stop taking the above medication(s) before starting the new medication?
 Yes No If yes, what is the washout period? _____

PRESCRIPTION PLEASE ATTACH COPIES OF PATIENT'S INSURANCE CARDS

SOLID TUMORS <input type="checkbox"/> AFINITOR <input type="checkbox"/> AFINITOR DISPERZ Dosage: _____ Sig: _____	<input type="checkbox"/> ALECENSA <input type="checkbox"/> BRAFTOVI <input type="checkbox"/> CABOMTYX <input type="checkbox"/> ERIVEDGE Sig: _____	<input type="checkbox"/> FEMARA <input type="checkbox"/> HYCAMTIN <input type="checkbox"/> INLYTA <input type="checkbox"/> IRESSA Sig: _____	<input type="checkbox"/> MEKINIST <input type="checkbox"/> MEKTOVI <input type="checkbox"/> NEXAVAR <input type="checkbox"/> NOLVADEX Sig: _____	<input type="checkbox"/> ODOMZO <input type="checkbox"/> RUBRACA <input type="checkbox"/> STIVARGA <input type="checkbox"/> SUTENT Sig: _____	<input type="checkbox"/> TAFINLAR <input type="checkbox"/> TAGRISSO <input type="checkbox"/> TARCEVA <input type="checkbox"/> TEMODAR QTY: _____ Refills: _____	<input type="checkbox"/> TYKERB <input type="checkbox"/> VERZENIO <input type="checkbox"/> VOTRIENT <input type="checkbox"/> XALKORI QTY: _____ Refills: _____	<input type="checkbox"/> XELODA <input type="checkbox"/> XTANDI <input type="checkbox"/> ZYKADIA <input type="checkbox"/> ZOLINZA QTY: _____ Refills: _____				
LIQUID TUMORS <input type="checkbox"/> BOSULIF <input type="checkbox"/> CALQUENCE Dosage: _____ Sig: _____	<input type="checkbox"/> EXJADE <input type="checkbox"/> FARYDAK <input type="checkbox"/> GLEEVEC QTY: _____ Refills: _____	<input type="checkbox"/> JADENU <input type="checkbox"/> JAKAFI <input type="checkbox"/> RYDAPT QTY: _____ Refills: _____	<input type="checkbox"/> SPRYCEL <input type="checkbox"/> TASIGNA <input type="checkbox"/> ZYDELIG QTY: _____ Refills: _____	SUPPORTIVE AGENTS <input type="checkbox"/> ARANESP <input type="checkbox"/> ARIXTRA Dosage: _____ Sig: _____				<input type="checkbox"/> EMEND <input type="checkbox"/> EPOGEN QTY: _____ Refills: _____	<input type="checkbox"/> GRANIX <input type="checkbox"/> LOVENOX <input type="checkbox"/> NEUPOGEN QTY: _____ Refills: _____	<input type="checkbox"/> NEULASTA <input type="checkbox"/> NPLATE <input type="checkbox"/> PROCRIT QTY: _____ Refills: _____	<input type="checkbox"/> XGEVA <input type="checkbox"/> ZOFRAN QTY: _____ Refills: _____
<input type="checkbox"/> KISQALI 200mg (must be administered in combination with other aromatase inhibitor) Sig: Take <input type="checkbox"/> 600 mg <input type="checkbox"/> 400 mg <input type="checkbox"/> 200 mg by mouth daily for 21 days followed by a 7 day rest period <input type="checkbox"/> Sig: with Letrozole 2.5 mg orally once daily throughout the 28-day cycle QTY: <input type="checkbox"/> 21 (200mg QD) <input type="checkbox"/> 42 (400mg QD) <input type="checkbox"/> 63 (600mg QD) Refills: _____				<input type="checkbox"/> COTELLIC Sig: Three tablets (60mg) for 21-days on and 7-days off, then repeat <input type="checkbox"/> ZELBORAF Sig: Four tablets (960mg) every 12 hrs QTY: 240 tabs Refills: _____							
<input type="checkbox"/> ERLEADA Sig: Take 4 tablets (240 mg) by mouth daily QTY: _____ Refills: _____ <i>Give w/ a gonadotropin-releasing hormone (GnRH) analog if the patient has not had a bilateral orchiectomy</i>				<input type="checkbox"/> TEMZOLOMIDE <input type="checkbox"/> 5 mg <input type="checkbox"/> 20 mg <input type="checkbox"/> 100 mg <input type="checkbox"/> 140 mg <input type="checkbox"/> 180 mg <input type="checkbox"/> 250 mg Sig: _____ QTY: _____ Refills: _____							
<input type="checkbox"/> POMALYST <input type="checkbox"/> THALOMID <input type="checkbox"/> REVLIMID <input type="checkbox"/> DEXAMETHASONE Adult Female of reproductive potential? <input type="checkbox"/> Yes <input type="checkbox"/> No Female Child of reproductive potential? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Male Child <input type="checkbox"/> Adult Male Dosage: _____ Sig: _____ QTY: _____ Refills: _____				<input type="checkbox"/> CAPECITABINE <input type="checkbox"/> 150 mg <input type="checkbox"/> 500 mg Sig: _____ QTY: _____ Refills: _____							
<input type="checkbox"/> IMBRUVICA Sig: _____ QTY: _____ Refills: _____ WM 420mg, CLL 420mg, cGVHD 420mg, SLL 420mg; MCL 560mg, MZL 560mg all dosed once daily				<input type="checkbox"/> NINLARO Sig: _____ mg once weekly on days 1, 8, and 15 of a 28-day cycle, 1 hour before or 2 hours after a meal QTY: 3 Refills: _____ <input type="checkbox"/> REVLIMID Sig: _____ mg for 21 days, then 7-days off, then repeat cycle QTY: 21 Refills: _____ <input type="checkbox"/> DEXAMETHASONE Sig: 40mg (10 tablets) once weekly on days 1,8,15, and 22 of a 28-day cycle QTY: 40 Refills: _____							
<input type="checkbox"/> IBRANCE Sig: QD w/ food for 21 days, then 7 days off QTY: 21 Refills: _____ Sig: <input type="checkbox"/> w/ Letrozole: 1 tablet (2.5 mg) QD QTY: 28 Refills: _____				<input type="checkbox"/> VENCLEXTA <input type="checkbox"/> Starter Pack: Week 1: 20mg po QD; Week 2: 50mg po QD; Week 3: 100mg po QD; Week 4: 200mg po QD <input type="checkbox"/> Maintenance: 400mg po QD after completing starter pack dosing <input type="checkbox"/> 10mg <input type="checkbox"/> 50mg <input type="checkbox"/> 100mg <input type="checkbox"/> 120 Bottle <input type="checkbox"/> Unit dose QTY: _____ Refills: _____							
OTHER _____ Dosage: _____ Sig: _____ QTY: _____ Refills: _____				<input type="checkbox"/> ALLOPURINOL Dosage: _____ Sig: _____ QTY: _____ Refills: _____							
OTHER _____ Dosage: _____ Sig: _____ QTY: _____ Refills: _____				<input type="checkbox"/> LONSURF <input type="checkbox"/> 15 mg/6.14 mg <input type="checkbox"/> 20 mg/8.19 mg QTY: _____ Refills: _____ Sig: Take _____ mg (35mg/m ² based on trifluridine component) 2x daily within 1 hr of completion of morning and evening meals on days 1 through 5 and days 8 through 12 of each 28-day cycle. (round dose to nearest 5mg, max of 80mg/dose)							

_____ = Restricted access medication as of June 2017

By signing this form and utilizing our services, you are authorizing BioMatrix Specialty Pharmacy, its subsidiaries and their employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies where allowed by law or contract.
Prescriber's Signature _____ Dispense as written (signature required. NO STAMPS) OR **Product Substitution Permitted (signature required. NO STAMPS)** **Date** _____

Prescriber's Email _____

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to BioMatrix Specialty Pharmacy or any of its subsidiaries using the contact information provided on this cover sheet. RF020_v2 08/18

Please visit WWW.BIOMATRIXSPRX.COM For more information